Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features

Journal of Obstetrics and Gynaecology Research

Volumn 38, Issue 1, 2012, Pages 57-64

  Wei, Wei ^a,b   Kong, Beihua ^a   Qu, Xun ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Hepatocyte growth factor; Ovarian cancer; Thrombospondin 1

Indexed keywords

MESSENGER RNA; SCATTER FACTOR; THROMBOSPONDIN 1;

ADENOMA; ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; OVARY ADENOMA; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION;

ADENOMA; ADULT; CARCINOMA; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; THROMBOSPONDIN 1;

EID: 84856262662     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2011.01695.x     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Van Golen CM, Schwab TS, Kim B et al. Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone. Cancer Res 2006; 66: 6570-6578. (Pubitemid 44085612)
3. Miyata Y, Ashida S, Nakamura T et al. Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivo. Biochem Biophys Res Commun 2003; 302: 892-897. (Pubitemid 36294060)
4. Chau GY, Lui WY, Chi CW et al. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection. Eur J Surg Oncol 2008; 34: 333-338.
5. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002; 13: 41-59. (Pubitemid 34436961)
6. Wong AS, Leung PC, Auersperg N. Hepatocyte growth factor promotes in vitro scattering and morphogenesis of human cervical carcinoma cells. Gynecol Oncol 2000; 78: 158-165. (Pubitemid 30650347)
7. Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 2004; 36: 1070-1078. (Pubitemid 38501558)
8. Yabkowitz R, Mansfield PJ, Dixit VM, Suchard SJ. Motility of human carcinoma cells in response to thrombospondin: Relationship to metastatic potential and thrombospondin structural domains. Cancer Res 1993; 53: 378-387. (Pubitemid 23031853)
9. Sheibani N, Frazier WA. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci USA 1995; 92: 6788-6792.
10. Bleuel K, Popp S, Fusenig NE, Stanbridge EJ, Boukamp P. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc Natl Acad Sci USA 1999; 96: 2065-2070. (Pubitemid 29117868)
11. Zhou HY,Wong AS. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 2006; 147: 2557-2566.
12. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: Cell signalling for invasive growth. Nat Rev Cancer 2002; 2: 289-300. (Pubitemid 37328782)
13. Wei W, Kong B, Yang Q, Qu X. Hepatocyte growth factor enhances ovarian cancer cell invasion through downregulation of thrombospondin-1. Cancer Biol Ther 2010; 9: 79-87.
14. Gallagher PG, Bao Y, Prorock A et al. Gene expression profiling reveals cross-talk between melanoma and fibroblasts: Implications for host-tumor interactions in metastasis. Cancer Res 2005; 65: 4134-4146. (Pubitemid 40775651)
15. Parrott JA, Skinner MK. Expression and action of hepatocyte growth factor in human and bovine normal ovarian surface epithelium and ovarian cancer. Biol Reprod 2000; 62: 491-500. (Pubitemid 30118287)
16. Ren Y, Cao B, Law S et al. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: A prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res 2005; 11: 6190-6197. (Pubitemid 41262947)
17. Toi M, Taniguchi T, Ueno T et al. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res 1998; 4: 659-664. (Pubitemid 28193565)
18. Baykal C, Demirtas E, Al A et al. Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int J Gynecol Cancer 2004; 14: 152-156. (Pubitemid 38280638)
19. Sowter HM, Corps AN, Smith SK. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int J Cancer 1999; 83: 476-480. (Pubitemid 29489861)
20. Nagy J, Curry GW, Hillan KJ et al. Hepatocyte growth factor/ scatter factor expression and c-met in primary breast cancer. Surg Oncol 1996; 5: 15-21. (Pubitemid 26235587)
21. Olivero M, Rizzo M, Madeddu R et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996; 74: 1862-1868. (Pubitemid 27007128)
22. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. Faseb J 1996; 10: 1183-1191. (Pubitemid 26276960)
23. Alvarez AA, Axelrod JR, Whitaker RS et al. Thrombospondin-1 expression in epithelial ovarian carcinoma: Association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Gynecol Oncol 2001; 82: 273-278. (Pubitemid 32730603)
24. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Pavlidis N. Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int J Gynecol Cancer 2006; 16 (Suppl 1): 241-246.
25. Grossfeld GD, Ginsberg DA, Stein JP et al. Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997; 89: 219-227. (Pubitemid 27073759)
26. Zabrenetzky V, Harris CC, Steeg PS, Roberts DD. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 1994; 59: 191-195. (Pubitemid 24343361)
27. Bertin N, Clezardin P, Kubiak R, Frappart L. Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: Correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res 1997; 57: 396-399. (Pubitemid 27081653)
28. Tanaka K, Sonoo H, Kurebayashi J et al. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma. Clin Cancer Res 2002; 8: 1125-1131. (Pubitemid 34517649)
29. Kwak C, Jin RJ, Lee C, Park MS, Lee SE. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 2002; 89: 303-309. (Pubitemid 34158467)
30. Maeda K, Nishiguchi Y, Yashiro M et al. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 2000; 5: 373-378.